Effect of Ayurveda Medicine in treatment of Cancer

Evaluation of sarpiguda on chemo radiation induced toxicities and quality of life in cancer patients a randomized open label study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/100759

Enrollment

Registered

2026-01-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site Health Condition 2: C159- Malignant neoplasm of esophagus, unspecified Health Condition 3: C069- Malignant neoplasm of mouth, unspecified Health Condition 4: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Consented patients advised for Concurrent Chemo Radiation therapy protocol of KCTRI ECOG less than or equal to 2 Acceptable Baseline Haematological and biochemical parameters Hb greater than 8mg par dl WBC greater than 4 into 10 power 9 per ml Platelet greater than 150 into 10 power 9 per ml Urea less than or equal to 40 mg per dl Creatinine less than or equal to 1.5 mg per dl Total bilirubin less than or equal to 1 mg per dl SGOT and SGPT less than or equal to 50 IU per ml

Exclusion criteria

Exclusion criteria: Unfit for Concurrent Chemo-Radiation therapy Know case of Diabetes mellitus Ischemic Heart Disease Thyroid Uncontrolled hypertension Second cancers Concomitant major illness requiring long term medication Any Major Illness

Design outcomes

Primary

Measure	Time frame
1 Quality of life assessed with EORTC QLQ C30 Version 3 and respective supplement European organization for research and treatment of cancer quality of life questionnaire 2 Biomarkers or Inflammatory Markers IL 6 TNF alphaTimepoint: 1 Quality of life will be assessed on baseline day 15 day 30 day 45 and post treatment 2 Biomarkers or Inflammatory markers will be assessed on baseline and post treatment	—

Measure

Time frame

1 Quality of life assessed with EORTC QLQ C30 Version 3 and respective supplement European organization for research and treatment of cancer quality of life questionnaire 2 Biomarkers or Inflammatory Markers IL 6 TNF alphaTimepoint: 1 Quality of life will be assessed on baseline day 15 day 30 day 45 and post treatment 2 Biomarkers or Inflammatory markers will be assessed on baseline and post treatment

—

Secondary

Measure	Time frame
1 Physical Endurance assessed by ECOG 2 Safety profile done as per KCTRI protocol Complete blood Count Serum Creatinine Serum Urea SGOT SGPT ALP and Total Bilirubin Total protein 3 Amelioration of adverse events Assesses with CTCEA Timepoint: 1 Physical Endurance assessed by ECOG will be assessed on baseline day 15 day 30 day 45 and post treatment 2 Safety profile done as per KCTRI protocol will be assessed on baseline and post treatment 3 Amelioration of adverse events Assesses with CTCEA will be assessed on baseline day 15 day 30 day 45 and post treatment	—

Measure

Time frame

1 Physical Endurance assessed by ECOG 2 Safety profile done as per KCTRI protocol Complete blood Count Serum Creatinine Serum Urea SGOT SGPT ALP and Total Bilirubin Total protein 3 Amelioration of adverse events Assesses with CTCEA Timepoint: 1 Physical Endurance assessed by ECOG will be assessed on baseline day 15 day 30 day 45 and post treatment 2 Safety profile done as per KCTRI protocol will be assessed on baseline and post treatment 3 Amelioration of adverse events Assesses with CTCEA will be assessed on baseline day 15 day 30 day 45 and post treatment

—

Countries

India

Contacts

Public ContactDr Santosh F Patil

KAHERs Shri BMK Ayurveda Mahavidhyalaya

santoshpatil.kaher@kleayurworld.edu.in9886633099

Outcome results